2. Search Result
Search Result
Results for "

neuropsychiatric diseases

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117516
    SR10067

    		REV-ERB Neurological Disease Metabolic Disease
    SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .
    SR10067
  • HY-148104
    ACSS2-IN-2
    1 Publications Verification

    		 Others Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC50 value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .
    ACSS2-IN-2
  • HY-154980
    GPR52 receptor modulator 1

    		Others Neurological Disease
    GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases .
    GPR52 receptor modulator 1
  • HY-128856
    P7C3-OMe

    		Others Neurological Disease
    P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .
    P7C3-OMe
  • HY-W909149
    TAAR1 agonist 3

    		Trace Amine-associated Receptor (TAAR) Adrenergic Receptor Neurological Disease
    TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC50=7.6). TAAR1 agonist 3 is also a full agonist of the α2A receptor (pEC50=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases .
    TAAR1 agonist 3
  • HY-W909173
    TAAR1 agonist 2

    		Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR Neurological Disease
    TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC50=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC50=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .
    TAAR1 agonist 2
  • HY-103522
    AA29504

    		GABA Receptor Neurological Disease
    AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABAA(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .
    AA29504
  • HY-E70395
    Prolyl endopeptidase

    PE; PEP

    		 Biochemical Assay Reagents Neurological Disease
    Prolyl Endopeptidase, highly active in brain and other tissues, catabolizes proline-containing peptides such as substance P, neurotensin, luteinizing hormone-releasing hormone, thyrotropin releasing hormone, bradykinin and angiotensin II. Prolyl Endopeptidase can be used for study of neuropsychiatric diseases such as stress disorder, depression, and schizophrenia .
    Prolyl endopeptidase
  • HY-15977
    (S)-P7C3-OMe

    		Others Neurological Disease
    (S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .
    (S)-P7C3-OMe
  • HY-169163
    BChE-IN-36

    		Carbonic Anhydrase Cholinesterase (ChE) Neurological Disease
    hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with KA values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC50 values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .
    BChE-IN-36
  • HY-123446
    JNJ-42259152

    		Others Neurological Disease
    JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .
    JNJ-42259152
  • HY-109112
    Brilaroxazine

    RP5063

    		 Dopamine Receptor 5-HT Receptor Neurological Disease Inflammation/Immunology
    Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .
    Brilaroxazine
  • HY-109112R
    Brilaroxazine (Standard)

    		Dopamine Receptor 5-HT Receptor Neurological Disease Inflammation/Immunology
    Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .
    Brilaroxazine (Standard)
  • HY-160637
    Lp-PLA2-IN-17

    		Phospholipase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2 .
    Lp-PLA2-IN-17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: